

ersonal use only



PainChek


Intelligent Pain Assessment

Quarterly update
April 2025


PHILIP DAFFAS, CEO & MD

PAINCHEK LTD | ASX:PCK

ersonal use only



Our purpose is to give
a **voice to people**
who **cannot reliably**
verbalise their pain



The Problem: Inadequate Pain Assessment in Non-Verbal Patients

US Federal and Local Requirements* for Compliance, Reimbursements and Quality Rating require Pain Management & Assessment Solutions for non-verbal Patients

PainChek's AI-enabled digital-first Pain Assessment solution drives better patient outcomes, and enables caregivers to stay compliant for while saving time and money



Millions globally suffer from conditions that impair their ability to self-report pain (e.g., dementia, cognitive disabilities, pre-verbal children)



Traditional pain assessment tools rely on subjective observation, leading to inconsistent and often inaccurate evaluations



Under-treated pain causes increased distress, reduced quality of life, and higher healthcare utilisation



Lack of standardised assessment in aged care, home care, and hospital settings contributes to misdiagnosis and suboptimal pain management



Time constraints and staff variability in care environments further reduce reliability and consistency of manual assessments

* Please see: CMS State Operations, Appendix PP - Certifications: F697 (Pain Management), F684 (Quality of Care); CMS MDS 3.0 (Minimum Data Set) - Reimbursement: Section J

THE BREADTH OF PAINCHEK'S GLOBAL MARKET OPPORTUNITY

400M

pre-verbal children¹



25-42%


of hospital beds occupied by
people with dementia^{4,5}



57M

people living with dementia

>150M expected by 2050^{2,3}



1. Ecology Communications Group. www.ecology.com/birth-death-rates
2. World Alzheimer Report 2016
3. Gerrossa et al. BMC Nursing (2019) 18:40

4. Tsai, I. P., Jeong, S. Y. S., & Hunter, S. (2018). Pain assessment and management for older patients with dementia in hospitals: an integrative literature review. *Pain Management Nursing*, 19(1), 54-71
5. Lancet Public Health – January 2022

PAINCHEK GLOBAL MARKET STRATEGY



**PainChek
Adult**



**Healthcare
Professionals**

BUSINESS MODEL

B2B Enterprise: licence

- Hospitals
- Care Homes
- Home care
- Primary Care

TARGET MARKETS/USERS

- Dementia &/geriatric wards
- ER/Post surgical care
- Residential & home care providers



**PainChek
Infant**



Home Carers

BUSINESS MODEL

B2C Direct to Carer Subscription licence

- Pharmacy services
- Retail stores
- Direct from supplier
- Apple/Google Play Store


TARGET MARKETS/USERS

- Mums & Dads
- Personal Home Carers
- Visiting healthcare professionals

PAINCHEK ADULT GLOBAL MARKET OPPORTUNITY



**PainChek
Adult**



LONG TERM CARE MARKET VALUE

	Aus	UK	US	ROW est	TOTAL
No. Aged Care Beds	0.22m	0.54m	1.7m	4.5m	6.96m
Annual Market Value @ A\$4 per bed per month	A\$11m	A\$26m	A\$100m	A\$216m	A\$350m

HOME CARE/CONSUMER MARKET VALUE

	Aus	EU	US	ROW est	TOTAL
No. of People living With Dementia at home	0.3m	5.6m	5.1m	32.4m	43.5m
Annual Market Value @ \$7 monthly subscription	A\$25m	A\$475m	A\$432m	A\$2,720 m	A\$3,655m

**47M people living
with dementia
globally –
estimated to
increase to 75M
by 2025 and 150M
by 2050**

¹ World Alzheimer Report 2016

² Alzheimer's Australia key facts & statistics 2017

^{3,4} Australian health care statistics

⁵ Estimated based on Australian dementia data ratios

⁶ Estimated based on Australian population ratios

⁷ Management Estimates

THE PAINCHEK® UNIVERSAL APP: QUICK AND EASY OPERATION

AI based micro-facial pain expression analysis:

- 3 second scan of patient face
- Recognises 9 micro-facial expressions indicative of pain

Guided digital questionnaire checklist:

- Guides the carer in other pain assessment factors e.g. movement, vocalisation etc.
- Questions with Yes/No decisions


Automated pain assessment score:

- 42 test points
- Generates overall pain severity score
- No pain, mild, moderate or severe and pain profile of the resident

Documented via cloud backend:


- Pain trend line and monitoring of treatment
- Capability to integrate into resident medical records
- Data analytics capability for audit and accreditation

Software-as-a-Medical Device enables mobile data capture



PAINCHEK ANALYTICS

Through PainChek®'s web portal, care managers can access real time dashboard reporting and data analytics to help draw actionable insights and assist their team in reducing clinical risk while improving their quality of care.



Pain data trends are graphed to assist caregivers in developing strategies for more effective pain management

Regular monthly reports are sent to administrators, including management summaries and benchmarking

Analytics are available via API for those businesses that wish to integrate reporting directly into their systems

FDA DE NOVO CLEARANCE PROJECTED Q2 2025



US FDA de Novo
Validation Study
delivers positive
results



Positive review
meeting held with
FDA in April - one
more meeting to
be scheduled in the
next weeks – on
target for clearance
in Q2 2025



Potential FDA
clearance for
PainChek's adult
app also provides a
predicate for its use
into home care,
infants & in other
market segments



**ON SUCCESSFUL CLEARANCE – PAINCHEK WILL BE THE ONLY REGULATORY
CLEARED PAIN ASSESSMENT TOOL FOR USE IN THE \$100M USD ANNUAL
LONG TERM CARE MARKET IN THE USA**

MARCH 2025 QUARTERLY HIGHLIGHTS: US FDA CLEARANCE ON TRACK POST FDA MEETING, IMPLEMENTATION GROWTH & POSITIVE INFANT APP PROGRESS



FDA clearance & US commercial market entry

- Positive F2F review meeting with FDA in April – clearance expected by 30 June 2025
- Access to \$100M USD long term care market opportunity
- US-based partners in place for rapid market entry upon approval




Continued acceleration in growth of PainChek Adult App

- 101k global licences – circa \$4.9m ARR once fully implemented – 12% growth on prior year
- 71K licences implemented – actual \$3.4m ARR – 17% increase on prior year
- Strong retention rates 85% + over past year



Direct to parent market entry of the Infant App

- Infant App now commercially available on Apple App store with initial sales in Australia
- Targeting Google Play Store in Q2 CY2025
- DTC partners producing strong parental comms for broader market push in Q2 CY2025



PainChek across Australia

Aged care's most popular digital clinical tool with large growth opportunities

- PainChek commercial licenses cover around **60,000 beds** and **750 aged care homes**, around **32% of total AU RAC market** and now **entering new home care and hospital clients**.

- AloyaCare, the largest provider of home care software in ANZ & Canada, extends its integration of PainChek into its home care solution.



NOTABLE EXISTING AUSTRALIAN AGED CARE CLIENTS (COVERING 25,000+ BEDS)




NOTABLE AGED CARE INTEGRATION PARTNERS CLIENTS PROVIDING ACCESS TO 400,00 AUSTRALIAN RAC & HOME CARE BEDS



PainChek Growing UK Footprint in a 500,000 bed Aged Care market

- PainChek commercial licences in UK aged care cover more **than 39,000 aged care beds and 1,000 care homes.**
- Implemented licences reach 24,000 – 80% growth on prior year



Personal use only

NOTABLE EXISTING UK AGED CARE CLIENTS COVERING 12,500 BEDS.

AGED CARE INTEGRATION PARTNERS PROVIDING ACCESS TO 400,000 UK RAC & HOME CARE BEDS

PAINCHEK PENETRATING UK ACUTE CARE MARKET (HOSPITALS)



- PainChek commenced the Edinburgh Royal Infirmary pilot in April 2025 to build an economic business case for rollout across a potential 21 hospitals in the region.
- An integration with TrakCare EMR system (InterSystems) in NHS Lothian has been completed, tested and is ready to be used with live patients in Edinburgh Royal Infirmary.
- TrakCare EMR is available across all 14 major NHS Health boards in Scotland providing the potential of deploying PainChek across 105 hospitals.



- PainChek has been validated in an acute hospital for the first time in UK, funded by the National Institute of Health and Care Research (NIHR).
- A paper titled *Evaluation of the psychometric properties of PainChek in older general hospital patients with dementia* has been published in the Journal of Age and Ageing in February 2025.
- The paper confirms PainChek's opportunity to be used in general hospitals for people living with dementia.
- There is a move away from paper based clinical tools; electronic documentation is more widespread in UK hospitals



PAINCHEK'S GROWING FOOTPRINT IN CANADIAN MARKET

PainChek has begun the commercialisation of the Canadian market, converting initial pilot clients into long term commercial agreements. Selling, training and support was all provided remotely from Australia, with a local team to be built out early in the new financial year (July).

EARLY ADOPTER CLIENTS IN THE CANADIAN MARKET



- ~**1000** licenses under long term contracts (**2+ years**) in the Canadian market
- Oakville Trafalgar Memorial Hospital contracted as part of a feasibility study
- From initial discussions, there appears to be a significant appetite for technology lead innovation in the Canadian market
- Majority of long-term care providers use the PointClickCare system
- PainChek presenting at the upcoming CHAA conference in Edmonton in collaboration with Sherwood Care and St Michael's Health Care Group

CLINICAL OUTCOMES FROM DEVONSHIRE DEMENTIA CARE HOME - UK

Devonshire Dementia Care Home in Surrey is a specialist dementia care home and day centre. PainChek®'s effectiveness was evaluated over four months at the home from August to November 2024. Residents' pain indicators were analysed for changes during this period. The analysis compared pain data from August and September 2024 to that of October and November 2024 to identify trends.

PainChek® data analysis identified a reduction in three pain indicator profiles that have been associated with falls and hospital admissions:

PainChek Indicators:

- **50% decrease** in altered random movement identified
- **37% decrease** in abnormal movement identified
- **46% decrease** in confusion identified

Resident Quality of Life Outcomes:

- **66% reduction** in hospital admission
- **33% reduction** in falls
- **50% reduction** in incidents and accidents


“Our staff can now assess pain levels quickly and accurately, even for residents with difficulty communicating discomfort. This has led to more timely and appropriate interventions, enhancing our residents' overall wellbeing. Our residents have expressed appreciation for the improved pain management, noting a better quality of life and reduced anxiety”

Manager at Devonshire Dementia Care Home

PainChek qualified pipeline exceeds 40,000 new licences – potentially doubling current ARR



Contracted ARR \$4.9M + Current Pipeline ARR \$1.8M \$6.7M Projected ARR




Existing pipeline includes ANZ, UK and Canada only

ersonal use only

CONSISTENT GROWTH IN CLINICAL UTILITY – WORLD’S LARGEST PAIN DATABASE

CUMULATIVE NUMBER OF
PAINCHEK® ASSESSMENTS



Over **10.2 million global pain assessments as of December 2025** conducted on the PainChek platform across **more than 150,000 residents**



105% increase in global pain assessments over the previous year in Aged Care alone



Strong ongoing growth quarter on quarter in clinical utility and implementation progress



More than 16,000 carers and health care professionals trained

In 12 months PainChek has doubled cumulative assessments to 10.2 million

Strong Global Traction: Implemented as a Medical Device in Senior Care Facilities Worldwide

Canada

- 300,000 aged care bed market
- PCK Adult Regulatory cleared
- Initial commercial clients now implemented & growing pipeline
- Established partners include PointClickCare and Alaya care

Europe (EU)

- Regulatory cleared & patent secured
- **German market:** Collaborative agreement with the University of Applied Sciences and Arts (HSBI) Bielefeld, Germany includes;
 - Phase 1: PainChek German App validation for 800,000 bed German market
 - Phase 2: Application for DiPA reimbursement for German home care market

UK

- ~37,500 beds licensed to use PCK
- 500,000 bed market opportunity
- 10+ integration partners
- Patent secured

Japan

- Patent secured
- Regulatory clearance process in progress

US / FDA *

- 1,700,000 aged care bed market opportunity
- FDA de Novo regulatory clearance projected May 2025
- Established go to market partnerships in place
- PCK BDM activities **establishing strong pipeline for rapid market entry**
- Patent secured

ANZ

- ~63,000 beds licensed to use PCK (30% share in 200,000 aged care bed market)
- 15+ integration partners
- Home care and Disabilities markets commenced

US MARKET ENTRY ACTIVITIES PROGRESSING POSITIVELY



Positive Client engagement during PointClickCare (PCC) US client conference April 2025 - PCC provide access to 1,000,000 North American Aged Care beds



FDA clinical data presentations at US based conferences in Q3/Q4 2025



Discussions advanced with additional new partners in the region



In U.S., CMS Mandates Pain Assessment in Skilled Nursing, Long Term, Hospice, & Home Care for compliance, reimbursement and quality ratings



ersonal use only

Meet PainChek[®] Infant

A PainChek Limited Product



PRE-VERBAL CHILDREN'S PAIN ASSESSMENT IS A LARGE GLOBAL MARKET OPPORTUNITY



CONSUMER PRE-VERBAL CHILDREN MARKET VALUE



Indicative App Price	A\$10/month
Net Revenue	A\$7/month
after app store commissions	
No. 0-3 year olds Worldwide	400m
No. Infants 0-1 year worldwide	150m
No. Infants 0-1 year in US, Europe and ANZ	10m

MARKET VALUE EXAMPLES

0.1% Global	400k subscribers =
Market Value	A\$33.6m Annualised Revenue
1% Global	4m subscribers =
Market Value	A\$336m Annualised Revenue

MEET PAINCHEK® INFANT

- The newest addition to the PainChek family, **PainChek Infant, is the world's first AI-enabled app for instant pain assessment** on infants aged 1-12 months
- Designed for **in-home use by parents or other non-medical carers**
- Globally, the Infant market **opportunity extends to up to 400 million pre-verbal children and 150 million born to first time parents each year**
- **Regulatory cleared for home use** in multiple markets including **ANZ, EU, UK and pending USA**



www.painchekinfant.com
www.infantpaincare.com

ersonal use only

PainChek Children's Market Strategy - to access 400 million pre-verbal children worldwide

B2C Consumer Market

Parents

Family

Daycare

B2B HCP Market

Hospital

GPs

OTs

Partnership Market

Integrations

MedTech

Pharma

Channels

- Ambassadors
- Social Media
- Specialists

- HCP Customers
- Publications
- Influencers

- Baby Monitors
- Pain medication orgs
- EHR

MEET PAINCHEK® INFANT

PainChek® Infant app is designed with parents and families in mind, offering a comprehensive user-friendly experience with a range of valuable features including:



3-second facial analysis-based pain assessment



Monitoring of historical pain events






Documenting treatments, including medications



Self-guided in-app training




User-friendliness in a non-clinical environment



PainChek Infant – Recent Milestones & Key Updates

App Live!

PainChek Infant app is live in the iOS app store – priced at \$99.99 for an annual subscription



Kiindred Promotion

133+ consumers applied to download the app

20 survey responses to help inform pricing, marketing, communications



App Store stats

Initial phase is a soft launch in Australia only

100+ downloads and initial DTC sales since launching on the Apple App Store!

626 app store page views



User generated content

4 x videos created by mums for future awareness campaigns and content



What's next?

Implement key learnings from the Kiindred survey

Finalize annual / monthly pricing options & test free trial period option


Commercial Launch phase 2 with marketing activities (goal 1,000 licenses)

Launch Android

Smart medical AI apps utilising smart devices for Smart Parenting


Facial Analysis

- Instant assessments – 3 seconds to scan face
- Log treatments
- Diarise events
- Uses device camera



Vocalisation

- Microphone analysis
- Cry of pain or no pain
- Smart phone "Shazam" version
- Integration with baby monitors



- [Technology-guided assessment of vocalisations and their diagnostic value as pain indicators for people living with dementia](#)

Infant Pain Care Strategy



- **Vocalisation AI feature**

- Cry/No Cry
- Pain/No Pain
- Shazam version
- Integration with baby monitors

- **Facial AI analysis**

- Multi-dimensional option for HCP's

- **Intervention**

- Pharma or non-pharma intervention

- **Facial AI analysis**

- Multi-dimensional option for HCP's



N.B. see thermometer example

CORPORATE SUMMARY

Top shareholders %

Peters Investments Proprietary Ltd	7.2%
Founders	4.1%
Board & key staff	4.0%

Financial information

Share price (30 th April 2025)	A\$0.034
---	----------

Shares on issue	1,841.9m
-----------------	----------

Market capitalisation	AUD \$64.4M
------------------------------	--------------------

Cash (31 March 2024)	A\$1.6M*
----------------------	----------

Debt	Nil
------	-----

Unlisted options/performance rights	475.5m
-------------------------------------	--------

* PainChek subsequently received \$1.41m in April 2025 for the FY24 R&D incentive refund.

1. US market entry

- **Achieve Adult App FDA clearance** – target June 30th 2025
- **Establish PainChek Corporation** & core team in USA
- **Complete initial sales** post FDA clearance
- **Expand local strategic partnerships**
- **FDA 510K application** for **Home Care** market





2. Continued growth of Adult App

- **Further Penetrate** Aged Care markets (ANZ, UK, Canada)
- **Drive towards operational break even** in ANZ and UK
- Expand further into **Home care sectors and hospital market**
- Complete **German market validation** work




3. Direct to parent market entry of the Infant App

- **Expand initial market entry** – App Store & Google Play store access **Q2 CY2025**
- **Broad Commercial launch** Q2 CY2025 onwards
- Build **B2C strategic partnerships** for global market penetration



THE TEAM



Philip Daffas
CEO & Managing Director, MBA, BSc

Philip is a highly accomplished global business leader & people manager. Philip has held senior global leadership positions with Cochlear & Roche in Europe, US & Australia.



Prof. Jeff Hughes
Chief Scientific Officer PhD, MPS

Jeff is a professor in the School of Pharmacy, Curtin University in Western Australia. Jeff is one of the team who developed the PainChek® concept.



Andrew Hoggan
Head of Operations

Andy is a Psychologist, management consultant, business leader & executive coach. Andrew has worked in both Australia & the UK across aged care & home care services.



Iain McAdam
CFO

Iain has over 20 years finance & transformational change experience within listed high growth multinational software & services companies, including iSoft & eServGlobal.



Scott Robertson
Chief Technology Officer, MBA, B.Eng.(Comp. Systems)

Scott has over 25 years' experience designing, deploying & managing enterprise software systems, adapting to changing client needs.



David Allsopp
Head of Business Development North America

David has extensive account management, relationship management. He is renowned for establishing trusting, transparent & long-standing relationships in the healthcare space.



Tandeep Gill
Head of Business Development Manager, UK

Tandeep is a registered pharmacist in both the hospital & community setting, with ten years experience in senior health & social care positions. He has spent three years leading the advancement of technology solutions in the UK.



Christelle Ucinck
Senior Business Development Manager, ANZ

Christelle is a registered pharmacist with 13+ years of experience, with expertise in pharmacy, aged care, and digital health innovation. She's held executive roles, scaling SaaS solutions and collaborating with key stakeholders to improve healthcare delivery and outcomes.

ersonal use only

THE BOARD



John Murray
Non-Exec Chair

25 years in tech & Venture Capital. Founder of Technology Venture Partners, ex Chair of Residential Aged Care provider. Multiple non-exec board roles.



Philip Daffas
CEO & Managing Director

Philip is a highly accomplished global business leader & people manager. Philip has held senior global leadership positions with Cochlear & Roche in Europe, US & Australia.



Ross Harricks
Non-Exec Director

Senior global medical device executive with Nucleus & experienced healthcare NED.



Adam Davey
Non-Exec Director

Corporate finance executive with extensive capital markets experience.



Cynthia Payne
Non-Exec Director

30 years executive leadership experience as well as significant board and operational experience in residential and home aged care services in Australia.

ersonal use only

ersonal use only



PainChek

Intelligent Pain Assessment

Quarterly update
April 2025

PHILIP DAFFAS, CEO & MD

PAINCHEK LTD | ASX:PCK